Cancer stem cells are a major cause of breast cancer relapse. However, there are no treatments that efficiently target those cells. Thus, there is an urgency in identifying novel treatments that specifically modulate cancer stem cells. Here, a robotic platform was developed to perform high-throughput drug screening based on mammosphere and anoikis resistance assays with human triple-negative breast cancer cells. The assay was validated by comparing the data generated by the developed platform and the classical manual protocols. The results show that there were no significant differences in the data generated with both methods. Moreover, with this new workflow, 3 out of 989 FDA-approved compounds were identified to target breast cancer stem cells. Overall, the researchers present a new device that could potentially boost cancer stem cell drug screening and identify highly efficient compounds to be used as adjuvant treatments.
Robotic mammosphere assay for high-throughput screening in triple-negative breast cancer
The IE from MS no longer understands current scripting languages, the latest main version (version 11) is from 2013 and has not been further developed since 2015.
Our recommendation: Use only the latest versions of modern browsers, for example Google Chrome, Mozilla Firefox or Microsofrt Edge, because only this guarantees you sufficient protection against infections and the correct display of websites!